Pimecrolimus versus topical corticosteroids in dermatology

Bibliography

• GUPTA AK, CHOW M: Pimecrolimus: a review. J. Eur. Acad. Dermatol. Venereol. (2003) 17(5):493-503.
   PubMed Web of Science ®Google Scholar
• WOLFF K, STUETZ A: Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin. Pharmacother. (2004) 5(3):643-655.
   PubMed Web of Science ®Google Scholar
• ASHCROFT DM, DIMMOCK P, GARSIDE R, STEIN K, WILLIAMS HC: Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials. BMJ. (2005) 330:516.
   PubMed Web of Science ®Google Scholar
• WOLLINA U, HANSEL G, KOCH A, ABDEL-NASER MB: Topical pimecrolimus for skin disease other than atopic dermatitis. Expert Opin. Pharmacother. (2006) 7(14):1967-1975.
   PubMed Web of Science ®Google Scholar
• SULZBERGER MB, WITTEN VH: The effect of topically applied compound F in selected dermatoses. J. Invest. Dermatol. (1952) 19(2):101-102.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, GRAEBER M, BRAUTIGAM M et al.: The novel ascomycin derivative SDZ ASM 981 is effective for psoriasis when used topically under occlusion. Br. J. Dermatol. (1998) 139:992-996.
   PubMed Web of Science ®Google Scholar
• LUGER T, VAN LEENT EJM, GRAEBER M et al.: SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br. J. Dermatol. (2001) 144:788-794.
   PubMed Web of Science ®Google Scholar
• MROWIETZ U, WUSTLICH S, HOEXTER G, GRAEBER M, BRÄUTIGAM M, LUGER T: An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta. Derm. Venereol. (2003) 83(5):351-353.
   Google Scholar
• RIGOPOULOS D, IOANNIDES D, KALOGEROMITROS D, GREGORIOU S, KATSAMBAS A: Pimecrolimus cream 1% versus betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial. Br. J. Dermatol. (2004) 151:1071-1075.
   PubMed Web of Science ®Google Scholar
• LUGER TA, LAHFA M, FÖLSTER-HOLST R et al.: Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J. Dermatolog. Treat. (2004) 15:169-178.
   PubMedGoogle Scholar
• COSKUN B, SARAL Y, TURGUT D: Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. Eur. J. Dermatol. (2005) 15(2):88-91.
   PubMed Web of Science ®Google Scholar
• FIROOZ A, SOLHPOUR A, GOROUHI F et al.: Pimecrolimus cream, 1%, versus hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch. Dermatol. (2006) 142(8):1066-1067.
   PubMedGoogle Scholar
• KREUTER A, SOMMER A, HYUN J et al.: 1% Pimecrolimus, 0.005% calcipotriol and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch. Dermatol. (2006) 142(9):1138-1143.
   PubMedGoogle Scholar
• MEINGASSNER JD, KOWALSKY E, SCHWENDINGER H, ELBE-BURGER A, STUTZ A: Pimecrolimus does not affect Langerhans cells in murine epidermis. Br. J. Dermatol. (2003) 149:853-857.
   PubMed Web of Science ®Google Scholar
• KALTHOFF ES, CHUNG J, MUSSER P, STUETZ A: Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin. Exp. Immunol. (2003) 133:350-359.
   PubMed Web of Science ®Google Scholar
• HOETZENECKER W, MEINGASSNER JG, ECKER R, STINGL G, STUETZ A, ELBE-BÜRGER A: Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J. Invest. Dermatol. (2004) 122:673-684.
   PubMed Web of Science ®Google Scholar
• HOETZENECKER W, ECKER R, STUETZ A, STINGL G, ELBE-BÜRGER A: Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. (2005) 115:1276-1283.
   PubMed Web of Science ®Google Scholar
• KRUMMEN MBW, VARGA G, STEINERT M, STUETZ A, LUGER TA, GRABBE S: Effect of pimecrolimus versus corticosteroids on murine bone marrow-derived dendritic cell differentiation, maturation and function. Exp. Dermatol. (2006) 15(1):43-50.
   PubMed Web of Science ®Google Scholar
• HOETZENECKER W, MEINDL S, STUETZ A, STINGL G, ELBE-BÜRGER A: Both pimecrolimus and corticosteroids deplete plasmatocytoid dendritic cells in patients with atopic dermatitis. J. Invest. Dermatol. (2006) 126:2141-2144.
   PubMedGoogle Scholar
• EUVRARD S, KANITAKIS J, CLAUDY A: Skin cancers after organ transplantation. N. Engl. J. Med. (2003) 348:1681-1691.
   PubMed Web of Science ®Google Scholar
• YAROSH D, PENA AV, NAY SL, CANNING MT, BROWN DA: Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J. Invest. Dermatol. (2005) 125:1020-1025.
   PubMed Web of Science ®Google Scholar
• CANNING MT, NAY SL, PENA AV, YAROSH DB: Calcineurin inhibitors reduce nuclear localization of transcription factor NFAT in UV-irradiated keratinocytes and reduce DNA repair. J. Mol. Hist. (2006) 37:285-291.
   PubMedGoogle Scholar
• DOELKER L, TRAN C, GKOMOUZAS A et al.: Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp. Dermatol. (2006) 15(5):342-346.
   PubMed Web of Science ®Google Scholar
• PITT M, GARSIDE R, STEIN K: A cost-utility analysis of pimecrolimus versus topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema. Br. J. Dermatol. (2006) 154:1137-1146.
   PubMed Web of Science ®Google Scholar
• CUNHA PR: Pimecrolimus cream 1% is effective in seborrhoeic dermatitis refractory to treatment with topical corticosteroids. Acta. Derm. Venereol. (2006) 86(1):69-70.
   Google Scholar
• MAYORAL FA, GONZALEZ C, SHAH NS, ARCINIEGAS C: Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology (2003) 207(3):322-323.
   PubMed Web of Science ®Google Scholar
• GRIBETZ C, LING M, LEBWOHL M et al.: Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J. Am. Acad. Dermatol. (2004) 51(5):731-738.
   PubMed Web of Science ®Google Scholar
• QUEILLE-ROUSSEL C, PAUL C, DUTEIL L et al.: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br. J. Dermatol. (2001) 144:507-513.
   PubMed Web of Science ®Google Scholar
• KAPP A, PAPP K, BINGHAM A et al.: Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J. Allergy Clin. Immunol. (2002) 110:277-284.
   PubMed Web of Science ®Google Scholar
• WAHN U, BOS JD, GOODFIELD M et al.: Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 110:e2.
   PubMed Web of Science ®Google Scholar
• BELSITO DV, FOWLER JF Jr, MARKS JG Jr et al.: Pimecrolimus cream 1%: a potential new treatment for chronic hand dermatitis. Cutis (2004) 73:31-38.
   PubMed Web of Science ®Google Scholar
• TAN JKL, MORNEAU K, FUNG K: Randomized controlled trial of pimecrolimus 1% cream for treatment facial acne vulgaris. J. Am. Acad. Dermatol. (2005) 52:738-739.
   PubMedGoogle Scholar
• LONSDALE-ECCLES AA, VELANGI S: Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series. Br. J. Dermatol. (2005) 153:390-394.
   PubMedGoogle Scholar